- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04955015
Associations of Carotid Plaque Characteristics With Brain Perfusion and Cognitive Function in Patients Undergoing CEA
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cerebrovascular disease is the first cause of death and adult disability in China. More than 75% of the patients in China have ischemic cerebrovascular disease, and about 33.3% of them have ipsilateral extracranial carotid stenosis. One of the main causes of carotid stenosis is atherosclerosis. Atherosclerotic plaques can be divided into two types: stable plaques and vulnerable plaques. Vulnerable plaque has the tendency to rupture, prone to thrombosis and rapid progression of dangerous plaque. Its pathological characteristics are mainly as follows: thin fibrous cap (or fibrous cap has been broken), large lipid nucleus, massive hemorrhage in plaque, rich in inflammatory cells, abundant neovascularization and plaque surface calcification. Vulnerable plaque is the main cause of stroke. At present, high-resolution magnetic resonance imaging combined with multi sequence is one of the best methods to evaluate carotid artery stenosis, which is helpful to analyze plaque characteristics.
At present, the main treatment methods of carotid artery stenosis are: carotid endarterectomy (CEA) and carotid angioplasty with stenting (CAS). Large scale multicenter prospective randomized trials and meta-analysis have established CEA as the gold standard for the treatment of carotid arerosclerotic stenosis.
Studies have shown that the ipsilateral cerebral perfusion is continuously decreased due to carotid artery stenosis, and CEA operation can relieve the vascular stenosis and improve the cerebral perfusion. However, the relationship between cerebral perfusion improvement after CEA and the quantitative characteristics of vulnerable plaque is still lack of sufficient evidence. Vascular cognitive impairment is closely related to the progress of carotid stenosis. The main mechanisms are microemboli formation, white matter injury and central nervous function decline caused by long-term chronic hypoperfusion. The formation and continuous hypoperfusion of microemboli further increase the burden of white matter disease. Studies have shown that the visual spatial executive ability, naming ability, attention ability and abstract profile ability of patients after CEA are significantly improved. However, there is still insufficient evidence about the relationship between the MRI features of vulnerable carotid plaques and the improvement of cognitive function after CEA.
We hope to achieve the following goals: 1) to explore the associations between carotid vulnerable plaque characteristics and cerebral perfusion in patients undergoing CEA; 2) to explore the associations between the characteristics of vulnerable carotid plaques and cognitive function in patients undergoing CEA.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Ran Huo, Dr.
- Phone Number: 010-82264374
- Email: ransmile216@163.com
Study Locations
-
-
-
Beijing, China
- Recruiting
- Peking University Third Hospital
-
Contact:
- Huishu Yuan, Dr.
- Phone Number: 010-82264188
- Email: huishuy@bjmu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Over 30 years old;
- The patients with symptomatic (>50%) or asymptomatic carotid stenosis (> 70%) measured by computed tomography angiography (CTA) or B-mode ultrasonography
- CEA operation will be performed in our hospital.
Exclusion Criteria:
- The history of CEA operation in the last 3 months;
- Diseases (AF, valve diseases, etc.) that may cause cardiac thrombosis;
- Contraindications of MR examination (vascular stent implantation, pacemaker, metal or magnetic plants in vivo, claustrophobia, etc.) were found;
- Contraindications of contrast agents: such as renal failure, iodine or gadolinium contrast agent allergy;
- Having heart or respiratory failure;
- Serious consciousness disorder (coma, etc.);
- Brain tumor;
- Acute cerebral hemorrhage;
- Pregnant women or planned pregnancies in the past 2 years;
- Who does not agree to sign the informed consent.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
patients
patients with caotid atherosclerosis refering to carotid endarterectomy
|
patients with carotid atherosclerosis refering to CEA
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
brain perfusion
Time Frame: From preoperative to 24 months after operation (CEA)
|
perioperative brain perfusion and changes of brain perfusion in patients underging CEA
|
From preoperative to 24 months after operation (CEA)
|
cognitive function
Time Frame: From preoperative to 24 months after operation (CEA)
|
perioperative cognitive function and cognitive changes in patients underging CEA
|
From preoperative to 24 months after operation (CEA)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- M2019292
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carotid Endarterectomy
-
Beijing Tiantan HospitalRecruitingCarotid EndarterectomyChina
-
University of California, DavisCompletedEndarterectomy, CarotidUnited States
-
Washington University School of MedicineTerminatedCarotid EndarterectomyUnited States
-
Beijing Tiantan HospitalNot yet recruiting
-
Cleveland Clinic Abu DhabiRecruitingCarotid EndarterectomyUnited Arab Emirates
-
Baylor Research InstituteAdmedus Regen Pty Ltd.Completed
-
University Hospital, Strasbourg, FranceUnknown
-
Peking University Third HospitalCompletedCarotid Endarterectomy | Coronary Artery Bypass GraftingChina
-
Salzburger LandesklinikenCompletedIntermediate Cervical Plexus Block for Carotid EndarterectomyAustria
-
University of DebrecenUnknownCerebral Oxygen Saturation,MCA Velocity,Intraoperative Neurological Symptoms During Carotid EndarterectomyHungary
Clinical Trials on carotid endarterectomy
-
Xuanwu Hospital, BeijingUnknownStroke | Carotid Stenosis | SurgeryChina
-
University Hospital OstravaRecruitingIn-Stent Carotid Artery RestenosisCzechia
-
Perouse MedicalEclevar MedtechCompletedStroke | Artery Stenosis | Artery Stenosis, Carotid | Occlusion of ArteryFrance
-
University of Campinas, BrazilUnknownCarotid Endarterectomy | Percutaneous Transluminal Angioplasty | Cognitive Aspects | Diffusion Weighted MRIBrazil
-
CAMC Health SystemCompletedStenoses, Carotid ArteryUnited States
-
IRCCS Policlinico S. DonatoUniversity of Pavia; Ministry of Health, ItalyCompleted
-
Ziv HospitalUnknownCarotid Artery StenosisIsrael
-
University of California, San DiegoWithdrawnStroke | Carotid StenosisUnited States
-
University of PecsCompletedCarotid Stenosis | Ischemia Reperfusion InjuryHungary
-
Xuanwu Hospital, BeijingShanghai Zhongshan Hospital; First Affiliated Hospital Xi'an Jiaotong University and other collaboratorsUnknownCarotid StenosisChina